Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
Date:2/26/2013

CHESTERBROOK, Pa., Feb. 26, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced financial results for the fourth quarter and the year ended December 31, 2012.  The Company also highlighted important recent commercial, regulatory and clinical development progress and provided financial guidance for 2013.

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO )

For the quarter ended December 31, 2012, Auxilium reported net revenues of $172.5 million compared to net revenues of $73.3 million in the fourth quarter of 2011.  For the full year 2012, Auxilium reported net revenues of $395.3 million compared to net revenues of $264.3 million for the full year 2011.  The fourth quarter 2012 net revenues include $93.6 million related to previously received and deferred up-front and milestone payments related to the Company's European collaboration with Pfizer, Inc. ("Pfizer") which were recognized as a result of the agreement to mutually terminate the collaboration effective April 24, 2013, as previously announced on November 7, 2012.For the quarter ended December 31, 2012, Auxilium reported net income of $90.5 million, or $1.83 per share, fully diluted, compared to a net loss of $(11.9) million, or $(0.25) per share, fully diluted, in the fourth quarter of 2011.  For the full year 2012, Auxilium's net income was $85.9 million, or $1.74 per share, fully diluted, compared to a net loss of $(32.9) million, or $(0.69) per share, fully diluted, for the full year 2011.  As a result of the agreement to mutually terminate the Pfizer European collaboration agreement, the Company recorded net income of $85.2 million in the fourth quarter results, reflecting the recognition of the $93.6 million in deferred revenues note
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Auxilium Announces Appointments to Enhance Leadership Team
2. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
3. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
4. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
5. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
6. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
7. Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
9. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
10. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
11. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... VA (PRWEB) October 01, 2014 ... Diagnostic, Clinical Therapeutics, Healthcare IT, and Laboratory Testing industries, ... regulatory positions at the director level and above from ... struggling to stay on top of rapid breakthroughs in ... result, many diagnostic companies have been forced to fold, ...
(Date:9/30/2014)... This news release is available in German . ... photonic crystal around several quantum dots in a semiconductor layer. ... a consequence of atomic processes. If a short laser pulse ... modified and the quantum dot experiences a change in the ... slow down the emission of light by the dot. As ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... and segments with highest potential revenues Do you ... updated report gives you revenue predictions for those ... For those therapies you find financial data, R&D ... analysis you get sales forecasts to 2024 at ...
(Date:9/30/2014)... California (PRWEB) September 30, 2014 ... the level of each type of cholesterol carrier or ... the presence of excessive cholesterol levels in the body, ... precursor condition to heart attack and other cardiovascular disorders. ... worldwide, therefore testing for cholesterol levels on a regular ...
Breaking Biology Technology:Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2Ultrafast remote switching of light emission 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4
... DIEGO, Aug. 4 Cadence Pharmaceuticals,Inc. (Nasdaq: ... and commercializing proprietary product candidates principally,for use in ... and CEO Theodore Schroeder will present the company,s ... -- Bank of America,s 2008 Specialty Pharmaceuticals Conference ...
... Revenue Increases 76% from Same Prior Year Period, ... SUPG ), a pharmaceutical company dedicated to ... solid tumors and,hematological malignancies, today announced financial results ... 30, 2008., Total revenues for the 2008 ...
... 4 Joseph F. Finn, Jr.,C.P.A. ("Finn") announced today ... to him on July 28, 2008 for the benefit ... a common law,procedure, wherein Finn will liquidate the assets, ... sealed bid auction on October 10, 2008., Persons ...
Cached Biology Technology:Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008 2SuperGen Reports 2008 Second Quarter Financial Results 2SuperGen Reports 2008 Second Quarter Financial Results 3SuperGen Reports 2008 Second Quarter Financial Results 4SuperGen Reports 2008 Second Quarter Financial Results 5SuperGen Reports 2008 Second Quarter Financial Results 6SuperGen Reports 2008 Second Quarter Financial Results 7SuperGen Reports 2008 Second Quarter Financial Results 8SuperGen Reports 2008 Second Quarter Financial Results 9SuperGen Reports 2008 Second Quarter Financial Results 10SuperGen Reports 2008 Second Quarter Financial Results 11SuperGen Reports 2008 Second Quarter Financial Results 12SuperGen Reports 2008 Second Quarter Financial Results 13
(Date:9/30/2014)... KONG , Sept. 30, 2014 Winners of ... Economist Events, Innovation Summit scheduled to take place at the JW ... the summit, the award winners will share their experiences and the ... who have made a proven innovation over the past decade, will ... the night before the summit. It will be the first ...
(Date:9/29/2014)... September 29, 2014 -- Plants have a ... help the pants extract nutrients and defend against ... from contaminating fruits and vegetables. Now, scientist have ... inside of seeds; thus ensuring that sprouting plants ... the University of Notre Dame, presented their findings ...
(Date:9/29/2014)... Food and Brand Lab pilot study, published in ... National School Lunch Program (NSLP) by 9% and overall ... Move to Schools (CMTS), an initiative of Michelle Obama,s ... to provide nutrition instruction to students and culinary advice ... event was held in an Upstate New York high ...
Breaking Biology News(10 mins):Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7Plants prepackage beneficial microbes in their seeds 2Chefs move to schools can increase school meal participation and vegetable intake among students 2
... At a recent Kavli Futures Symposium, 19 experts from ... the lab to understand and exploit the evolution of organisms ... or other biotechnology products. Now, three of the participants ... raised during the meeting: Michael Brenner, Professor of Applied Mathematics ...
... Tampa, Fla. (June 28, 2011) Mensenchymal stem cells ... tissues, have been shown to be therapeutically effective in ... assisting in skin wound healing, and suppressing chronic airway ... are being prepared for therapeutic applications, they are cultured ...
... device to reduce the risk of infection, clotting and narrowing ... because of kidney failure. The device, designed to be ... a technician easy access to the patient,s bloodstream and could ... of a dialysis procedure. The prototype has not yet ...
Cached Biology News:Beyond Darwin: Evolving new functions 2Serum-free cultures help transplanted MSCs improve efficacy 2Student team invents device to cut dialysis risk 2
...
Human Cystatin A MAb (Clone 224705)...
... Molecular Probes is pleased to offer ... the ultrasensitive detection of primary amines. ... Indiana University, the ATTO-TAG reagents are ... (OPA), naphthalene-2,3-dicarboxaldehyde (NDA) and anthracene-2,3-dicarboxaldehyde, all ...
...
Biology Products: